Tempus AI $TEM

Health Care · NASDAQ

$54.04
-5.57 (-9.34%)
As of Nov 20, 2026, 4:05 PM EST
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 21, 2026, the first target we tracked for TEM.

Tempus AI (TEM) is trading down at $54.04 (-9.34%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: June 14, 2024 · $37.00 offering · NASDAQ

Analyst price targets on TEM

Current price targets from 3 firms average $81.7, median $75, ranging from $70 to $100 — the average is 51% above the current $54. Each is tracked to its date and scored the same way a member's call is.

3 targets, newest first. Open a row for its source and scoring.

DateNov 3, 2026 FirmBTIG RatingBuy · raises Targetat $77.8 · $100 +29% Horizonby Nov 2027 StatusOpen

Entry price $77.8, the close nearest Nov 3, 2026, when the target was reported; the target is +29% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source BTIG raises Tempus AI stock price target to $100 on data deals Investing.com · Nov 3, 2026 · opens the publisher's site
BTIG raised its price target on Tempus AI Inc (NASDAQ:TEM) shares to $100 from $80
DateNov 3, 2026 FirmJefferies RatingHold · raises Targetat $77.8 · $70 -10% Horizonby Nov 2027 StatusOpen

Entry price $77.8, the close nearest Nov 3, 2026, when the target was reported; the target is -10% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70 Investing.com · Nov 3, 2026 · opens the publisher's site
Jefferies upgraded Tempus AI Inc (NASDAQ:TEM) from Underperform to Hold and raised its price target to $70.00 from $35.00.
DateSep 21, 2026 FirmGoldman Sachs RatingNeutral · initiates Targetat $78 · $75 -4% Horizonby Sep 2027 StatusOpen

Entry price $78, the close nearest Sep 21, 2026, when the target was reported; the target is -4% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.

Scoring Open: judged on the close on Sep 21, 2027.

Source Goldman Sachs initiates Tempus AI stock coverage with neutral rating Investing.com · Sep 21, 2026 · opens the publisher's site
with a Neutral rating and a price target of $75.00 on Monday.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Tempus AI revenue & net income history (FY2022–FY2025)

RevenueNet incomeNet margin (right axis, %)
$1.27B$283.0M−$705.8MFY2022 revenue: $320.7MFY2022 net income: −$289.8M · Net margin −90.4%'22FY2023 revenue: $531.8MFY2023 net income: −$214.1M · Net margin −40.3%'23FY2024 revenue: $693.4MFY2024 net income: −$705.8M · Net margin −101.8%'24FY2025 revenue: $1.27BFY2025 net income: −$245.0M · Net margin −19.3%'25−69.4%−50%0%50%FY2022 net margin: −90.4% (off the scale, which stops at −69.4%)FY2023 net margin: −40.3%FY2024 net margin: −101.8% (off the scale, which stops at −69.4%)FY2025 net margin: −19.3%
Tempus AI annual financial statements
FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$320.7M$531.8M$693.4M$1.27B
Growth (year over year)—+65.8%+30.4%+83.4%
Operating income−$265.4M−$196.1M−$691.1M−$252.9M
Operating margin−82.8%−36.9%−99.7%−19.9%
Net income−$289.8M−$214.1M−$705.8M−$245.0M
Net margin−90.4%−40.3%−101.8%−19.3%
EPS (diluted)−$5.30−$4.20−$6.23−$1.41
Balance sheet
Cash and equivalents$302.9M$165.8M$341.0M$604.8M
Total assets—$564.1M$926.1M$2.27B
Total liabilities—$840.7M$869.8M$1.78B
Shareholders' equity−$1.13B−$1.38B$56.3M$491.3M
Cash flow
Operating cash flow−$168.2M−$214.3M−$189.0M−$218.1M
Capital expenditure$18.4M$34.6M$22.1M$21.0M
Free cash flow−$186.6M−$248.9M−$211.2M−$239.1M
Dividends paid$5.63M$5.63M$5.63M$0

From Tempus AI's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Tempus AI in the news

Nov 19, 2026 Investing.com Tempus AI CEO Ryan Fukushima sells $645,720 in stock
Nov 19, 2026 Investing.com Tempus AI chief accounting officer Ryan Bartolucci sells $97,045 in stock
Nov 19, 2026 The Motley Fool Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?
Nov 9, 2026 PR Newswire SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
Nov 3, 2026 Investing.com BTIG raises Tempus AI stock price target to $100 on data deals Target
Show 5 older stories
Nov 3, 2026 Investing.com Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70 Target
Nov 2, 2026 CNBC Stocks making the biggest moves midday: Oracle, SpaceX, Tempus AI, Rivian & more
Oct 30, 2026 Investing.com Cathie Wood’s ARK sells Eli Lilly stock, buys Tempus AI and Coinbase
Sep 22, 2026 Yahoo Finance Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test
Sep 21, 2026 Investing.com Goldman Sachs initiates Tempus AI stock coverage with neutral rating Target
Tracked from this story

Also mentions Goldman Sachs

About Tempus AI

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

Source: Wikipedia — Tempus AI

Headquarters
Chicago, Illinois From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →

Mentioned with Tempus AI in recent news